Xeris Biopharma Holdings Inc
NASDAQ:XERS

Watchlist Manager
Xeris Biopharma Holdings Inc Logo
Xeris Biopharma Holdings Inc
NASDAQ:XERS
Watchlist
Price: 3.09 USD 1.64% Market Closed
Market Cap: 460.4m USD
Have any thoughts about
Xeris Biopharma Holdings Inc?
Write Note

Xeris Biopharma Holdings Inc
Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Xeris Biopharma Holdings Inc
Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
Xeris Biopharma Holdings Inc
NASDAQ:XERS
Operating Expenses
-$197.6m
CAGR 3-Years
-24%
CAGR 5-Years
-12%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Operating Expenses
-$36.5B
CAGR 3-Years
1%
CAGR 5-Years
0%
CAGR 10-Years
-2%
Bristol-Myers Squibb Co
NYSE:BMY
Operating Expenses
-$24.9B
CAGR 3-Years
2%
CAGR 5-Years
-24%
CAGR 10-Years
-11%
Pfizer Inc
NYSE:PFE
Operating Expenses
-$29.4B
CAGR 3-Years
-11%
CAGR 5-Years
1%
CAGR 10-Years
-2%
Merck & Co Inc
NYSE:MRK
Operating Expenses
-$26.7B
CAGR 3-Years
-11%
CAGR 5-Years
-7%
CAGR 10-Years
-4%
Eli Lilly and Co
NYSE:LLY
Operating Expenses
-$18.6B
CAGR 3-Years
-12%
CAGR 5-Years
-10%
CAGR 10-Years
-5%
No Stocks Found

Xeris Biopharma Holdings Inc
Glance View

Market Cap
460.4m USD
Industry
Pharmaceuticals

Xeris Biopharma Holdings, Inc. is a holding company. The company is headquartered in Chicago, Illinois and currently employs 294 full-time employees. The company went IPO on 2018-06-21. The firm is focused on developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The firm has three commercial products: Gvoke, Keveyis and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. Its product candidate also includes Ogluo (EU), Self-Administered Glucagon for prevention, Levothyroxine and XP-9164. The firm uses its non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize its products.

XERS Intrinsic Value
2.99 USD
Overvaluation 3%
Intrinsic Value
Price

See Also

What is Xeris Biopharma Holdings Inc's Operating Expenses?
Operating Expenses
-197.6m USD

Based on the financial report for Sep 30, 2024, Xeris Biopharma Holdings Inc's Operating Expenses amounts to -197.6m USD.

What is Xeris Biopharma Holdings Inc's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-12%

Over the last year, the Operating Expenses growth was -13%. The average annual Operating Expenses growth rates for Xeris Biopharma Holdings Inc have been -24% over the past three years , -12% over the past five years .

Back to Top